B Part of It
The B Part of It study was rolled out in stages across South Australia during 2017 and 2018. A total of 237 schools participated, giving all year 10, 11 and 12 students in 2017 the opportunity to participate and receive the meningococcal B vaccine (Bexsero®) free. Each registered school was visited by immunisation nurses throughout the two years. At their school visit, students received throat swabs, as well as two vaccinations, to provide protection against the potentially deadly Meningococcal B disease.
The herd immunity study examined if the licensed and recommended meningococcal B vaccine reduced the spread of meningococcal bacteria in teenagers by immunising a large community group. The study was led by the University of Adelaide in partnership with SA Health and was approved by the Women’s and Children’s Health Network Human Research Ethics Committee.
The final throat swabs were completed for across the state in July 2018.
Throughout the study:
- Over 34,400 high school students participated in having a baseline swab collected and over 55,700 swabs were taken.
- Over 58,000 doses of Men B vaccine in were administered.
- 88% of students, who were in Years 10 and 11 in 2017, received 2 doses of the vaccine.
- 80 immunisation providers were involved delivering the study across South Australia.
- The B Part of It team trained over 250 nurses, and administration staff across South Australia.
The B Part of It team wish to thank everybody who participated in this study and who helped make it possible. By being part of this, you helped drive global understanding around protection against meningococcal B.
The B Part of It study is the largest study of its kind in the world and was only made possible through the willing participation and support from the South Australian community.